Sign In
Buy PRN
$247.56
+1.45 (+0.588%)
At Close: Jun 03, 2026
ETFs in Focus Post Hawkish Powell Speech
11:17am, Monday, 28'th Aug 2023
The Federal Reserve Chair Jerome Powell in the Jackson Hole symposium warned that the central bank is prepared to raise interest rates further and keep the borrowing costs high until inflation comes i
Why There May Be Growing Opportunities In The Industrial Sector
12:52am, Saturday, 22'nd Jul 2023
The industrial sector could be poised for a lift as mega spending projects kick in. Why capital investment in infrastructure has been lagging.
5 ETF Zones Primed for 2023 Growth Amid Rate Hike Prospects
12:39pm, Friday, 23'rd Jun 2023
Here are a few zones and their ETFs that could potentially experience the positive effects of a hawkish Fed.
From Coffee Cups To Disposable Trays, Packaging Stock Shows Growth Trend Ahead Of Earnings
03:54pm, Wednesday, 01'st Feb 2023
Packaging stock Graphic Packaging is near a buy point ahead of earnings. Stellar earnings and technical ratings support the stock.
NEW YORK, Nov. 17, 2022 /PRNewswire/ -- Metalworking Machinery Accessories Market Research Report by Accessories, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Profound Medical to Present at the 2022 Jefferies London Healthcare Conference
09:30pm, Tuesday, 08'th Nov 2022 GlobeNewswire Inc.
TORONTO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets cu
Profound Medical Corp. (PROF) Q3 2022 Earnings Call Transcript
06:13pm, Saturday, 05'th Nov 2022
Profound Medical Corp. (NASDAQ:PROF ) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Stephen Kilmer - IR Dr. Arun Menawat - CEO Rashed Dewan - CFO Conference Call Par
Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow
08:30pm, Thursday, 13'th Oct 2022 GlobeNewswire Inc.
TORONTO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets cu
Profound Medical to Participate in September Investor Conferences
08:30pm, Tuesday, 06'th Sep 2022 GlobeNewswire Inc.
TORONTO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets c
Industry Outlook 2022: Bracing For The Energy Impact
01:07pm, Monday, 05'th Sep 2022
The manufacturing sector continues to be plagued by supply chain problems while demand is weakening. A post-pandemic reshuffle is in the making, with demand weakening and supply becoming less disrupte
Profound Medical Provides TULSA-PRO® Reimbursement Update
04:05pm, Friday, 02'nd Sep 2022 GlobeNewswire Inc.
TORONTO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets c
5 Momentum ETFs Riding on the Surge in Market
03:58pm, Monday, 22'nd Aug 2022 Zacks Investment Research
Momentum investing would be a winning strategy in the current market environment for those seeking higher returns in a short spell.
5 Momentum ETFs Riding on the Surge in Market
01:33pm, Monday, 22'nd Aug 2022
Momentum investing would be a winning strategy in the current market environment for those seeking higher returns in a short spell.
Profound Medical Corp. (PROF) CEO Dr. Arun Menawat on Q2 2022 Results - Earnings Call Transcript
11:30am, Sunday, 07'th Aug 2022
Profound Medical Corp. (NASDAQ:PROF ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Stephen Kilmer - IR Dr. Arun Menawat - CEO Rashed Dewan - CFO Conference Call Parti
Profound Medical to Release Second Quarter 2022 Financial Results on August 4 – Conference Call to Follow
08:30pm, Thursday, 14'th Jul 2022 GlobeNewswire Inc.
TORONTO, July 14, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets cu
